Lookout for collaborators
We are always on the lookout for collaborators. Academic research, start-up or pharmaceutical industry. If you are excited...
LIQOMICS The future of cancer diagnostics
At LIQOMICS we strive to improve cancer treatment. Requiring only a blood sample, we use circulating tumor DNA to understand the genetics of an individual cancer and monitor treatment with razor-sharp sensitivity.
About
Who we are
LIQOMICS is an academic spin-off company from Cologne, Germany. We aspire to bring our cutting-edge liquid biopsy technology for genotyping and disease monitoring to patients worldwide.
Highly sensitive MRD detection
The Liqomics MRD test is a crucial tool for the early detection of low level MRD in cancer patients. With our proprietary workflow and bioinformatics we detect cancer with higher sensitivity than others. This can enable an earlier intervention in case of a relapse and hence an improved disease outcome for the patients.
Some key statistics of our assay
Sensitivity for Genotyping (SNPs / InDels) > 93%
Specificity for Genotyping (SNPs / InDels) > 99.999%
Sensitivity for MRD detection at MRD level > 10-5 > 88%
Specificity for MRD detection at MRD level > 10-5 > 99%
Limit of Detection for MRD ~ 5 x 10-6
What makes us different
Our proprietary technology allows us to be more sensitive and specific when it comes to genotyping and MRD detection across cancers. This is crucial in situations of low disease burden.
LIQOMICS
COMPETITORS
Input Material
Only blood needed
Often tumor tissue needed
Detection Threshhold
Few DNA molecules per million (10-6)
Mostly higher (10-3-10-5)
Applicability
All cancers
Often only specific cancers
Design Principle
Universal assay for all patients with a type of cancer
Often patient-individual assay with high assay costs
Features
MRD, Genotying and additional bespoke features easily possible
often only one feature
LIQOMICS
COMPETITORS
Applicability
Platform applicable to all cancers
Often only applicable to specific cancers
Features
MRD, Genotyping, additional features possible
Often only MRD or Genotyping
Design principle
Universal assay for all patients with a particular cancer or group of cancers making assay cheaper
Often individual assay for patients needed with high assay costs
Detection threshold for MRD
Few cancer DNA molecules per million (10-6)
Mostly higher (10-3-10-5)
Input material
Only blood needed
Often tumor-informed approach, tumor tissue needed
Learn more about our assay
Our assay uses tumor mutations that we identify and track in blood to inform on the genetic drivers of a tumor and to quantify minimal residual disease (MRD)
Publications
Here are some publications from our early development showing applications in Hodgkin Lymphoma and CNS Lymphoma.
Testimonials
What Patients Say About Us
Vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint eiusmod tempor incididunt ut labore et dolore magna aliqua
Vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint eiusmod tempor incididunt ut labore et dolore magna aliqua
Vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint eiusmod tempor incididunt ut labore et dolore magna aliqua
Our Blog
Lates News & Articles